1. Início
  2. Faculdade de Medicina - FM
  3. Departamento de Radiologia e Oncologia - FM/MDR
  4. Artigos e Materiais de Revistas Científicas - FM/MDR
Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/29431
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorARAI, Roberto J.
dc.contributor.authorPETRY, Vanessa
dc.contributor.authorHOFF, Paulo M.
dc.contributor.authorMANO, Max S.
dc.date.accessioned2018-11-21T17:00:50Z
dc.date.available2018-11-21T17:00:50Z
dc.date.issued2018
dc.identifier.citationBIOMARKER RESEARCH, v.6, article ID 20, 6p, 2018
dc.identifier.issn2050-7771
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/29431
dc.description.abstractMetronomic therapy has been gaining importance in the neoadjuvant setting of breast cancer treatment. Its clinical benefits may involve antiangiogenic machinery. Cancer cells induce angiogenesis to support tumor growth by secreting factors, such as vascular endothelial growth factor (VEGF). In breast cancer, Trastuzumab (TZM) based treatment is of key importance and is believed to reduce diameter and volume of blood vessels as well as vascular permeability. Here in we investigated serum levels of angiogenic factors VEGF and MCSF in patients receiving metronomic neoadjuvant therapy with or without TZM. We observed in HER2+ cohort stable levels of MCSF through treatment, whereas VEGF trend was of decreasing levels. In HER2- cohort we observed increasing levels of MCSF and VEGF trend. Overall, HER2+ patients had better pathological response to treatment. These findings suggest that angiogenic pathway may be involved in TZM anti-tumoral effect in the neoadjuvant setting.
dc.description.sponsorshipBrazilian National Council of Scientific and Technology Development, CNPq
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofBiomarker Research
dc.rightsopenAccess
dc.subjectMetronomic chemotherapy
dc.subjectAngiogenesis
dc.subjectBiomarker
dc.subjectNeoadjuvant
dc.subjectBreast cancer
dc.subject.otherendothelial growth-factor
dc.subject.otherrenal-cell carcinoma
dc.subject.otherangiogenic activity
dc.subject.othertrial
dc.subject.othertherapy
dc.subject.otherbevacizumab
dc.subject.othercyclophosphamide
dc.subject.othertrastuzumab
dc.subject.otherdocetaxel
dc.subject.othercombination
dc.titleSerum levels of VEGF and MCSF in HER2+/HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
dc.typearticle
dc.rights.holderCopyright BMC
dc.identifier.doi10.1186/s40364-018-0135-x
dc.identifier.pmid29946467
dc.subject.wosMedicine, Research & Experimental
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
hcfmusp.description.articlenumber20
hcfmusp.description.volume6
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000436112200001
hcfmusp.origem.id2-s2.0-85062927509
hcfmusp.publisher.cityLONDON
hcfmusp.publisher.countryENGLAND
hcfmusp.relation.referenceBocci G, 2002, CANCER RES, V62, P6938
hcfmusp.relation.referenceBottini A, 2006, J CLIN ONCOL, V24, P3623, DOI 10.1200/JCO.2005.04.5773
hcfmusp.relation.referenceBrowder T, 2000, CANCER RES, V60, P1878
hcfmusp.relation.referenceCameron D, 2013, LANCET ONCOL, V14, P933, DOI 10.1016/S1470-2045(13)70335-8
hcfmusp.relation.referenceDANFORTH DN, 1990, AM SURGEON, V56, P6
hcfmusp.relation.referenceDellapasqua S, 2011, BREAST, V20, P319, DOI 10.1016/j.breast.2011.02.014
hcfmusp.relation.referenceDvorak HF, 1999, AM J PATHOL, V149, P1029
hcfmusp.relation.referenceEmmenegger U, 2010, RECENT RESULTS CANC, V180, P165, DOI 10.1007/978-3-540-78281-0_10
hcfmusp.relation.referenceEscudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
hcfmusp.relation.referenceEubank TD, 2003, J IMMUNOL, V171, P2637, DOI 10.4049/jimmunol.171.5.2637
hcfmusp.relation.referenceGianni L, 2013, J CLIN ONCOL, V31, P1719, DOI 10.1200/JCO.2012.44.7912
hcfmusp.relation.referenceHeer K, 2001, CLIN CANCER RES, V7, P3491
hcfmusp.relation.referenceIzumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b
hcfmusp.relation.referenceKalsi T, 2014, BRIT J CANCER, V111, P2224, DOI 10.1038/bjc.2014.496
hcfmusp.relation.referenceKang H, 2013, KOREAN J ANESTHESIOL, V64, P402, DOI 10.4097/kjae.2013.64.5.402
hcfmusp.relation.referenceKerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369
hcfmusp.relation.referenceLange T, 2011, CANCER LETT, V308, P54, DOI 10.1016/j.canlet.2011.04.013
hcfmusp.relation.referenceLawicki S, 2016, ONCOTARGETS THER, V9, P911, DOI 10.2147/OTT.S99959
hcfmusp.relation.referenceLoven D, 2008, ACTA ONCOL, V47, P104, DOI 10.1080/02841860701472470
hcfmusp.relation.referenceMackey JR, 2015, J CLIN ONCOL, V33, P141, DOI 10.1200/JCO.2014.57.1513
hcfmusp.relation.referenceMotzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
hcfmusp.relation.referenceMunoz R, 2005, BREAST, V14, P466, DOI 10.1016/j.breast.2005.08.026
hcfmusp.relation.referenceMunzone E, 2017, CANCER LETT, V400, P259, DOI 10.1016/j.canlet.2016.12.041
hcfmusp.relation.referenceOsada T, 2008, CANCER IMMUNOL IMMUN, V57, P1115, DOI 10.1007/s00262-007-0441-x
hcfmusp.relation.referencePasquier E, 2007, CURR CANCER DRUG TAR, V7, P566, DOI 10.2174/156800907781662266
hcfmusp.relation.referencePasquier E, 2010, NAT REV CLIN ONCOL, V7, P455, DOI 10.1038/nrclinonc.2010.82
hcfmusp.relation.referencePetry V, 2015, BRAZ J MED BIOL RES, V48, P479, DOI 10.1590/1414-431X20144354
hcfmusp.relation.referenceRice A, 2002, J CLIN PATHOL, V55, P569, DOI 10.1136/jcp.55.8.569
hcfmusp.relation.referenceSchneider BP, 2008, J CLIN ONCOL, V26, P4672, DOI 10.1200/JCO.2008.16.1612
hcfmusp.relation.referenceSCHWARTZ GF, 1994, CANCER, V73, P362, DOI 10.1002/1097-0142(19940115)73:2<362::AID-CNCR2820730221>3.0.CO;2-L
hcfmusp.relation.referenceSlamon DJ, 2013, CANCER RES, V73, DOI 10.1158/0008-5472.SABCS13-S1-03
hcfmusp.relation.referenceSledge GW, 2015, J CLIN ONCOL, V33, P133, DOI 10.1200/JCO.2014.58.1298
hcfmusp.relation.referenceSweeney CJ, 2001, CANCER RES, V61, P3369
hcfmusp.relation.referenceTran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399
hcfmusp.relation.referenceTuck MK, 2009, J PROTEOME RES, V8, P113, DOI 10.1021/pr800545q
hcfmusp.relation.referenceVoron T, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00070
hcfmusp.relation.referenceWildiers H, 2018, LANCET ONCOL, V19, P323, DOI 10.1016/S1470-2045(18)30083-4
hcfmusp.relation.referenceWolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775
hcfmusp.relation.referenceWong NS, 2010, J CLIN ONCOL, V28, P723, DOI 10.1200/JCO.2009.24.0143
hcfmusp.relation.referenceYen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.E02-02-0084
dc.description.indexPubMed
hcfmusp.citation.scopus7-
hcfmusp.scopus.lastupdate2024-03-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDR
Departamento de Radiologia - FM/MDR

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - LIM/24
LIM/24 - Laboratório de Oncologia Experimental

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_ARAI_Serum_levels_of_VEGF_and_MCSF_in_HER2HER2_2018.PDFpublishedVersion (English)711.06 kBAdobe PDFThumbnail
View/Open
Show simple item record

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.